You are seeing a free-to-access but limited selection of the activity Altmetric has collected about this research output.
Click here to find out more.
X Demographics
Mendeley readers
Attention Score in Context
| Title |
Progressive Brain Atrophy and Cortical Thinning in Schizophrenia after Commencing Clozapine Treatment
|
|---|---|
| Published in |
Neuropsychopharmacology, April 2015
|
| DOI | 10.1038/npp.2015.90 |
| Pubmed ID | |
| Authors |
Mohamed Ahmed, Dara M Cannon, Cathy Scanlon, Laurena Holleran, Heike Schmidt, John McFarland, Camilla Langan, Peter McCarthy, Gareth J Barker, Brian Hallahan, Colm McDonald |
| Abstract |
Despite evidence that clozapine may be neuroprotective, there are few longitudinal MRI studies that have specifically explored an association between commencement of clozapine treatment for schizophrenia and changes in regional brain volume or cortical thickness. Thirty-three patients with treatment resistant schizophrenia and 31 healthy controls (HC) matched for age and gender underwent structural MRI brain scans at baseline and 6-9 months after commencing clozapine. MRI images were analysed using SIENA (Structural Image Evaluation, using Normalisation, of Atrophy) and FreeSurfer to investigate changes over time in brain volume and cortical thickness respectively. Significantly greater reductions in volume were detected in the right and left medial prefrontal cortex and in the periventricular area in the patient group regardless of treatment response. Widespread further cortical thinning was observed in patients compared to healthy controls. The majority of patients improved symptomatically and functionally over the study period, and patients who improved were more likely to have less cortical thinning of the left medial frontal cortex and the right middle temporal cortex. These findings demonstrate on-going reductions in brain volume and progressive cortical thinning in patients with schizophrenia who are switched to clozapine treatment. It is possible that this grey matter loss reflects a progressive disease process irrespective of medication use or that it is contributed to by switching to clozapine treatment. The clinical improvement of most patients indicates that antipsychotic related grey matter volume loss may not necessarily be harmful or reflect neurotoxicity.Neuropsychopharmacology accepted article preview online, 01 April 2015. doi:10.1038/npp.2015.90. |
X Demographics
The data shown below were collected from the profiles of 4 X users who shared this research output. Click here to find out more about how the information was compiled.
Geographical breakdown
| Country | Count | As % |
|---|---|---|
| Unknown | 4 | 100% |
Demographic breakdown
| Type | Count | As % |
|---|---|---|
| Members of the public | 4 | 100% |
Mendeley readers
The data shown below were compiled from readership statistics for 97 Mendeley readers of this research output. Click here to see the associated Mendeley record.
Geographical breakdown
| Country | Count | As % |
|---|---|---|
| Japan | 1 | 1% |
| United Kingdom | 1 | 1% |
| Chile | 1 | 1% |
| Italy | 1 | 1% |
| Unknown | 93 | 96% |
Demographic breakdown
| Readers by professional status | Count | As % |
|---|---|---|
| Student > Ph. D. Student | 16 | 16% |
| Researcher | 13 | 13% |
| Student > Master | 12 | 12% |
| Student > Bachelor | 11 | 11% |
| Student > Doctoral Student | 6 | 6% |
| Other | 22 | 23% |
| Unknown | 17 | 18% |
| Readers by discipline | Count | As % |
|---|---|---|
| Medicine and Dentistry | 19 | 20% |
| Neuroscience | 15 | 15% |
| Psychology | 12 | 12% |
| Nursing and Health Professions | 7 | 7% |
| Biochemistry, Genetics and Molecular Biology | 6 | 6% |
| Other | 16 | 16% |
| Unknown | 22 | 23% |
Attention Score in Context
This research output has an Altmetric Attention Score of 11. This is our high-level measure of the quality and quantity of online attention that it has received. This Attention Score, as well as the ranking and number of research outputs shown below, was calculated when the research output was last mentioned on 25 March 2023.
All research outputs
#3,204,530
of 25,018,122 outputs
Outputs from Neuropsychopharmacology
#1,532
of 4,406 outputs
Outputs of similar age
#39,649
of 270,324 outputs
Outputs of similar age from Neuropsychopharmacology
#51
of 85 outputs
Altmetric has tracked 25,018,122 research outputs across all sources so far. Compared to these this one has done well and is in the 87th percentile: it's in the top 25% of all research outputs ever tracked by Altmetric.
So far Altmetric has tracked 4,406 research outputs from this source. They typically receive a lot more attention than average, with a mean Attention Score of 21.0. This one has gotten more attention than average, scoring higher than 64% of its peers.
Older research outputs will score higher simply because they've had more time to accumulate mentions. To account for age we can compare this Altmetric Attention Score to the 270,324 tracked outputs that were published within six weeks on either side of this one in any source. This one has done well, scoring higher than 85% of its contemporaries.
We're also able to compare this research output to 85 others from the same source and published within six weeks on either side of this one. This one is in the 40th percentile – i.e., 40% of its contemporaries scored the same or lower than it.